Jpn. J. Pharmacol. 75 (2), 195-198 (1997)

Possible Involvement of Rapamycin-Sensitive Pathway in Bcl-2 Expression in Human Neuroblastoma SH-SY5Y Cells

Yoshihisa Kitamura (1), Tadashi Kosaka (1), Shun Shimohama (2), Yasuyuki Nomura (3) and Takashi Taniguchi (1,*)

(1) Department of Neurobiology, Kyoto Pharmaceutical University, Kyoto 607, Japan
(2) Department of Neurology, Faculty of Medicine, Kyoto University, Kyoto 606, Japan
(3) Department of Pharmacology, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo 060, Japan
(*) To whom correspondence should be addressed.

Abstract: In human neuroblastoma SH-SY5Y cells, treatment with immunosuppressants such as FK506, cyclosporin A or rapamycin for 4 days induced the enhancement of the 27-kDa Bcl-2alpha protein level. Among immunosuppressants, rapamycin has most potency. Treatment with herbimycin A or wortmannin also enhanced Bcl-2 expression, but the BB type of platelet-derived growth factor decreased the level. These results suggest that Bcl-2 expression is probably regulated by the cascade of tyrosine kinase, phosphatidylinositol 3-kinase and rapamycin-sensitive p70 S6-kinase in human neuroblastoma SH-SY5Y cells.

Keywords: Bcl-2, Rapamycin, p70 S6-kinase

Copyrightę The Japanese Pharmacological Society 1997

[Back to TOC]